Rayner Surgical v. Somerset Therapeutics — Ophthalmic Injection Patent Transfer
Rayner Surgical Inc. and Rayner Intraocular Lenses Ltd. brought a three-patent infringement action against Somerset Therapeutics LLC in the District of New Jersey, targeting stable preservative-free mydriatic and anti-inflammatory ophthalmic injection solutions. After 145 days, the case was transferred to the Trenton vicinage under a new docket, keeping the dispute live without any merits ruling.
Three ophthalmic patents, one intra-district transfer, and a live dispute
On 6 September 2024, Rayner Surgical Inc. and its affiliate Rayner Intraocular Lenses Ltd. filed suit against Somerset Therapeutics LLC in the United States District Court for the District of New Jersey, asserting infringement of three patents — US9486406B2, US9066856B2, and US9855246B2 — each directed at stable preservative-free mydriatic and anti-inflammatory solutions formulated for ocular injection. The plaintiffs are established players in the intraocular lens and surgical ophthalmic space, and the patents in suit represent core formulation IP in the post-surgical eye-care segment.
Rather than proceeding to substantive litigation in the Newark or Camden vicinage where it was originally filed, the case was transferred on 29 January 2025 to the Trenton vicinage of the same District of New Jersey, receiving the new docket number 3:24-cv-9017. This is an intra-district administrative reassignment, not a transfer to a different federal circuit; the case remains within the Third Circuit and no change in applicable law resulted. No merits determination, claim construction order, or preliminary injunction ruling was issued before the transfer.
The 145-day period from filing to transfer suggests the reassignment was driven by administrative or judge-assignment factors rather than a contested venue motion, though the public record does not specify the precise trigger. Somerset Therapeutics, represented by Saiber LLC, had only one identified agent of record, which may indicate early-stage proceedings at the time of transfer. With three formulation patents in play and a generic or biosimilar ophthalmic product at stake, the substantive infringement and validity questions remain entirely open.
Filing to Case Transferred in 145 days
145 days from filing to transfer — relatively swift venue reassignment within the same district
What the Trenton transfer means for Rayner v. Somerset
Intra-district transfer: same court, new vicinage
An intra-district transfer within the District of New Jersey moves a case between vicinages — here, from the original filing location to Trenton — without changing the governing circuit law or federal jurisdiction. The case simply continues under a new docket number (3:24-cv-9017) before a different judge assignment. No merits ruling, claim construction, or dispositive motion is affected by the transfer itself.
Administrative reassignmentRayner’s claims survive intact; litigation clock resets administratively
For Rayner Surgical and Rayner Intraocular Lenses, the transfer is procedurally neutral. All three asserted patents remain live, and the infringement action continues on the same factual and legal footing. Rayner loses no rights and concedes no ground by virtue of the intra-district reassignment; the case simply proceeds before a new judge in Trenton.
Claims fully preservedSomerset faces the same exposure under new docket number
Somerset Therapeutics’ litigation risk is unchanged by the transfer. Infringement liability across three formulation patents remains in dispute, and any statute-of-limitations or damages exposure continues to accrue. The Trenton reassignment offers no substantive defence advantage; Somerset must still answer the infringement allegations on the merits before the transferee judge.
Risk unchangedOphthalmic injection market remains under IP cloud
For companies active in preservative-free mydriatic and anti-inflammatory ophthalmic formulations, this transfer signals that Rayner’s enforcement campaign is ongoing, not resolved. Three granted US patents covering the relevant formulation space remain asserted, and any competitor or potential market entrant should treat the Trenton docket as the live enforcement vehicle to monitor for claim construction and injunction developments.
Active enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | RAYNER SURGICAL INC. | Company | Ophthalmic surgical company — holder of US9486406B2, US9066856B2, and US9855246B2Search in Eureka ↗ |
| Co-Plaintiff | RAYNER INTRAOCULAR LENSES LTD. | Company | Search in Eureka ↗ |
| Defendant | Somerset Therapeutics, LLC | Company | Somerset Therapeutics LLC — specialty pharmaceutical company named as accused infringer of ophthalmic formulation patentsSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for RAYNER SURGICAL INC.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for RAYNER SURGICAL INC.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for RAYNER SURGICAL INC.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing RAYNER SURGICAL INC.Search in Eureka ↗ |
| Defendant counsel | Katherine Ann Escanlar. | Attorney | Counsel for Somerset Therapeutics, LLCSearch in Eureka ↗ |
| Defendant law firm | Saiber LLC | Law Firm | Representing Somerset Therapeutics, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The transfer order reflects a purely administrative intra-district reassignment; the docket entry contains no merits ruling, no infringement finding, and no validity determination. The Trenton vicinage will inherit the case at its earliest procedural stage, meaning all substantive questions — claim construction, infringement, and validity of the three Rayner formulation patents — remain entirely open. Parties and observers should treat the new 3:24-cv-9017 docket as the operative case record going forward.
US9486406B2, US9066856B2 & US9855246B2 — Preservative-Free Ophthalmic Injection Formulations
US9486406B2, US9066856B2, and US9855246B2 each relate to stable, preservative-free formulations designed for intraocular or periocular injection, combining mydriatic agents (which dilate the pupil) with anti-inflammatory compounds. The application dates span multiple years, suggesting a deliberate prosecution strategy to build layered patent protection around a clinically important product category used in cataract and other anterior-segment surgical procedures. The ‘preservative-free’ designation is clinically significant because preserved formulations carry ocular toxicity risks that limit use in sensitive post-surgical eyes.
From a competitive intelligence standpoint, three granted patents with distinct application lineages represent a meaningful formulation barrier for any generic or branded competitor seeking to enter the US market for combination mydriatic/anti-inflammatory injectables. The patents’ survival through examination and grant implies the USPTO found the claimed formulations non-obvious over prior art — a signal that validity challenges will require robust prior-art searches and potentially expert declarations. Rayner’s willingness to assert all three patents simultaneously against Somerset Therapeutics suggests confidence in the portfolio and an intent to deter broader market entry.
Should you run an FTO against US9486406B2, US9066856B2 & US9855246B2?
Any pharmaceutical or ophthalmic company developing, manufacturing, or planning to commercialise preservative-free mydriatic or anti-inflammatory injection products for ocular use in the United States should treat these three Rayner patents as priority FTO targets. This case confirms that Rayner is actively enforcing the portfolio; a product reaching the market without a clearance opinion carries meaningful infringement exposure. The risk is particularly acute for ANDA or 505(b)(2) filers targeting combination ophthalmic injectables.
PatSnap Eureka’s FTO Search Agent can map each of the three asserted patent claim sets against your specific formulation parameters — active ingredient concentrations, excipient profiles, and delivery method — to identify freedom corridors or design-around opportunities. Eureka’s citation graph also surfaces any continuation or divisional applications that may extend Rayner’s coverage beyond the three currently asserted patents, giving R&D and regulatory teams a complete picture before committing to a commercialisation pathway.
Run a freedom-to-operate analysis on US9486406B2 to assess your product’s exposure
Run FTO in Eureka →Similar ophthalmic formulation patent cases in NJ District Court
Explore related preservative-free ophthalmic and pharmaceutical formulation patent suits filed in the District of New Jersey involving comparable IP enforcement strategies.
What this case signals for the ophthalmic formulation IP landscape
Rayner’s three-patent assertion against a specialty pharma defendant highlights rising enforcement activity in preservative-free ophthalmic injection formulations.
Three-patent stacks raise the invalidity burden for accused infringers
Asserting US9486406B2, US9066856B2, and US9855246B2 simultaneously forces Somerset to mount invalidity challenges across multiple patent families. Each patent likely covers distinct formulation or method claims, making a single prior-art reference unlikely to knock out the entire assertion. Defendants in multi-patent ophthalmic cases typically face higher settlement pressure as a result.
Intra-district transfers can signal early scheduling disputes or judge-load management
A transfer to Trenton within 145 days of filing, without any visible contested motion, is consistent with administrative judge-assignment balancing in New Jersey. Practitioners should monitor the Trenton docket for a new scheduling order, which will set the operative claim construction and trial timeline for this dispute.
RAYNER v Somerset — key questions answered
Rayner Surgical Inc. and Rayner Intraocular Lenses Ltd. sued Somerset Therapeutics LLC in the District of New Jersey on 6 September 2024, asserting infringement of three patents — US9486406B2, US9066856B2, and US9855246B2 — covering stable preservative-free mydriatic and anti-inflammatory ophthalmic injection solutions. The case was transferred to the Trenton vicinage on 29 January 2025 and continues under docket 3:24-cv-9017.
The docket records the transfer as an administrative intra-district reassignment to the Trenton vicinage of the District of New Jersey. The public record does not specify whether a party filed a transfer motion or whether the reassignment was sua sponte for judge-load balancing. No merits ruling preceded the transfer, and the case retains the same governing law and circuit jurisdiction.
The accused products are described in the complaint as stable preservative-free mydriatic and anti-inflammatory solutions for injection — a category of ophthalmic combination products used to dilate the pupil and control inflammation, typically in the context of cataract or anterior-segment surgery. The specific Somerset Therapeutics product formulation at issue is not publicly detailed in the available docket records.
All three patents were granted by the USPTO and are asserted as live in this 2024 infringement action, which is consistent with them being in force at the time of filing. Patent term and any post-grant proceedings (IPR or ex parte reexamination) should be independently verified through the USPTO Patent Center, as the public litigation record alone does not confirm current maintenance fee status.
Following the 29 January 2025 transfer, the case was assigned docket number 3:24-cv-9017 in the Trenton vicinage of the United States District Court for the District of New Jersey. Parties, counsel, and observers monitoring this litigation should track the Trenton docket for all subsequent filings including scheduling orders, claim construction proceedings, and dispositive motions.
PatSnap Eureka searches patents and litigation data to answer instantly.